Product Description
Mechanisms of Action: Angiogenesis Inhibitor,Apoptosis Stimulant
Novel Mechanism: No
Modality: Large Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sloan Kettering Medical Center
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Prostate Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
NCT00695851 | P1 |
Completed |
Prostate Cancer |
2009-03-01 |